ZyVersa Therapeutics, Inc.
ZVSA
$0.7151
$0.00711.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 90.42% | 76.20% | 75.86% | -601.11% | -596.03% |
| Total Depreciation and Amortization | -33.65% | -178.10% | 75.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -98.95% | -83.04% | -83.18% | 8,570.02% | 2,365.52% |
| Change in Net Operating Assets | -64.24% | -108.01% | -104.96% | -46.03% | -54.03% |
| Cash from Operations | 13.32% | 6.38% | -2.37% | 13.14% | -78.39% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -65.72% | -39.64% | -2.51% | -- | -- |
| Repurchase of Common Stock | -- | 100.00% | 100.00% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | 100.00% | 97.80% | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 75.73% | 53.82% | 24.25% | -2,115.12% | -2,344.60% |
| Cash from Financing | -0.06% | 261.16% | 1,764.02% | 502.71% | 219.30% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 41.88% | 80.90% | 98.74% | 109.85% | 8.55% |